Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes

被引：0

作者：

Taylor, K ^{[1
]}

Kim, D ^{[1
]}

Bicsak, T ^{[1
]}

Heintz, S ^{[1
]}

Varns, A ^{[1
]}

Aisporna, M ^{[1
]}

Fineman, M ^{[1
]}

Baron, A ^{[1
]}

机构：

[1] Amylin Pharmaceut Inc, San Diego, CA USA

来源：

DIABETOLOGIA | 2002年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

123

引用

页码：A43 / A44

页数：2

共 50 条

[1] Continuous subcutaneous infusion of AC2993 (Synthetic exendin-4) provides sustained, day-long glycemic control to patients with type 2 diabetes
Taylor, K
Kim, D
Bicsak, T
Heintz, S
Varns, A
Aisporna, M
Fineman, MS
Baron, A
DIABETES, 2002, 51 : A85 - A85
[2] Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes
Buse, J
Fineman, M
Gottlieb, A
Gaines, E
Kolterman, O
DIABETES, 2000, 49 : A100 - +
[3] 28 days of treatment with AC2993 (synthetic exendin-4) improved glycemic control in patients with Type 2 diabetes concomitantly treated with metformin (met) and/or sulfonylurea (sfu)
Fineman, M
Bicsak, T
Shen, L
Taylor, K
Gaines, E
Varns, A
Kim, D
Baron, A
DIABETOLOGIA, 2002, 45 : A44 - A44
[4] AC2993 (synthetic exendin-4) lowered postprandial plasma glucose concentrations in people with type 2 diabetes.
Kolterman, O
Fineman, M
Gottlieb, A
Petrella, E
Pricket, K
Young, A
DIABETOLOGIA, 1999, 42 : A41 - A41
[5] Subcutaneous injection of AC2993 (Synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with type 2 diabetes
Kim, D
Taylor, K
Bicsak, T
Wang, Y
Aisporna, M
Heintz, S
Fineman, MS
Baron, A
DIABETES, 2002, 51 : A104 - A104
[6] Stimulation of endogenous insulin secretion by subcutaneous AC2993 (synthetic exendin-4) in healthy overnight fasted volunteers
Kolterman, O
Young, G
Parker, J
Amin, D
Prickett, K
DIABETES, 1999, 48 : A199 - A199
[7] AC2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with Type 2 diabetes
Kim, D
Taylor, K
Bicsak, T
Wang, Y
Aisporna, M
Heintz, S
Fineman, M
Baron, A
DIABETOLOGIA, 2002, 45 : A44 - A44
[8] Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC2993) in subjects with type 2 diabetes
Fineman, M
Young, A
Gaines, E
Prickett, K
DIABETES, 2000, 49 : A106 - A106
[9] Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes
Kolterman, O
Gottlieb, A
Prickett, K
Gaines, E
Young, A
DIABETES, 2000, 49 : A114 - A114
[10] Five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes reduces post-prandial glucose, glucagon and triglyceride concentrations
Kolterman, O
Gottlieb, A
Gaines, E
Fineman, M
DIABETOLOGIA, 2000, 43 : A189 - A189

← 1 2 3 4 5 →